35 years of experience
Formerly with Arcelor
and Laboratoires Fournier
Founder in 2001
26 years of experience
Formerly with Fournier Labs, Solvay, Plasto Santé
Joined in 2013
30 years of experience
Formerly Ipsen,
Advanz pharma, Exeltis
Joined in 2016
28 years of experience
Formerly with IDS, Axess Vision
Joined in 2023
24 years of experience
Formerly with Savoye, DS Smith
Joined in 2022
18 years of experience
Formerly with Fournier Labs, Abbott, Solvay, Inventiva
Joined in 2021
27 years of experience
Formerly with Xequel Bio, Santen, Eyevance, Sunovion, Galderma, Sanofi-Dermik
Joined in 2024
Philippe MONNOT is the co-leader of Gemmes Venture, which he co-founded in 1999. GEMMES VENTURE is a founding member of various companies in the healthcare sector (ASTEN SANTÉ, H2AD TELEHEALTH, VIVALIB), as well as in digital services, fintech, and cleantech. GEMMES VENTURE was also the first shareholder of CROSSJECT. Philippe MONNOT is a graduate of EM LYON.
Dr. Jean-Francois LOUMEAU practiced medicine from 1981 to 1985 before holding numerous roles in the pharmaceutical industry in France and internationally, particularly in commercial fields and subsidiary management, from 1985 to 2005.
He served on the Supervisory Board of a French pharmaceutical manufacturing company from 2007 to 2013. Since then, he has held Non-Executive Director positions in unlisted pharmaceutical companies in France and Europe, as well as advisory roles for private equity funds in acquisitions of industrial sites or pharmaceutical product portfolios.
Recently, he joined the Advisory Board of E-SANA, a young French start-up specializing in ultraportable diagnostic tools for POCT (Point-Of-Care Tests).
Dr. Jean-Francois LOUMEAU graduated from the FACULTY OF MEDICINE PARIS VI – PIERRE AND MARIE CURIE UNIVERSITY. He also holds a degree from ESSEC BUSINESS SCHOOL (1985).
Eric NEMETH is a professional investor, Advisor to STEED CAPITAL, and founder of MACEINVEST1, a business angel fund, following a career in the banking and financial sector.
He served as a member of the Executive Committee of DEUTSCHE BANK in France, CEO of WORMS BANK and DETROYAT ASSOCIÉS, after working for STERN BANK and BANEXI.
Eric NEMETH began his career at the SAINT-GOBAIN GROUP, where he held various positions, including Head of Corporate Finance and Investor Relations, from 1982 to 1989.
Dr. Yannick PLETAN practiced medicine as Head of the Pulmonology Department at the Menton Hospital and collaborated on numerous research projects with INSERM.
He then held executive positions in the pharmaceutical industry for over 20 years (SANOFI, INSTITUT DE RECHERCHE PIERRE FABRE, PFIZER, ROCHE), contributing to successful product launches.
Dr. PLETAN now advises innovative biotech companies in Europe and the United States on development strategies, as well as medical and regulatory approaches.
Daniel TEPER is a pharmaceutical industry leader and entrepreneur based in the United States. He holds a Doctor of Pharmacy degree from the UNIVERSITY of PARIS SACLAY and a Master of Business Administration from INSEAD.
He has held executive roles in several pharmaceutical companies, including GLAXO LABORATORIES and DELAGRANGES. He was also a Global Partner at EURORSCG HAVAS HEALTH and a Partner at ISO HEALTHCARE CONSULTING.
Daniel TEPER is the Founder of multiple companies, including WINTEC PHARMA and IMMUNE PHARMACEUTICALS. He currently serves as the CEO of CYTOVIA THERAPEUTICS, where he is the principal Founder.
Copyright © 2024 CROSSJECT – VERSION BETA TEST
With over 25 years of experience in key sectors of the commercial pharmaceutical industry, he brings expertise in corporate governance and business fevelopment, market access, sales management, marketing, and commercial operations.
He joined CROSSJECT after serving as Director of Commercial Operations at XEQUEL BIO, where he was responsible for commercialization strategy and pre-commercial activities for assets funded by BARDA and the U.S. NATIONAL INSTITUTES OF HEALTH (NIH), as well as acquired commercial assets.
Throughout his career, he has held multiple leadership positions in commercial roles within major international specialized pharmaceutical companies. Notably, he served as interim U.S. Commercial Director and Vice President of Market Access and Commercial Channels at SANTEN PHARMACEUTICALS following the acquisition of EYEVANCE PHARMACEUTICALS. In this role, Tony TIPTON assumed various commercial responsibilities for the U.S. region and generated over $70 million in gross revenue for U.S. commercial operations.
He also served as Account Director at SUNOVION PHARMACEUTICALS, where he was responsible for integrated health systems and launched a new epilepsy treatment, APTIOM. At GALDERMA LABORATORIES, he held several positions in sales and marketing.
Olivier LACOMBE has over 20 years of experience in pharmaceutical R&D, with significant expertise in managing multidisciplinary projects and interactions with regulatory authorities and partners.
He has held leadership positions in several major pharmaceutical companies, including FOURNIER, SOLVAY, ABBOTT, and more recently, INVENTIVA, where he served as Director of Research Projects in both clinical and non-clinical phases. He has also led operational departments, participated in steering committees, and contributed to multiple international project teams focused on various aspects of drug development.
As Director of Pharmaceutical Development, Olivier LACOMBE is one of the key points of contact for CROSSJECT’s partners.
He holds a PhD in pharmacology/pharmacokinetics from UNIVERSITÉ PAUL SABATIER TOULOUSE.
Marianne SVENSSON has over 25 years of experience in finance and administration across multiple sectors.
Before joining CROSSJECT in 2022, she led the administrative and financial operations of the international packaging company DS SMITH, based in London. Marianne SVENSSON also managed all aspects related to the commercial premises at the DUCHE DE BOURGOGNE in dijon and served as financial controller at the supply chain solutions company SAVOYE.
Marianne SVENSSON holds a master’s degree from the GÖTEBORG BUSINESS SCHOOL and a dual degree in economics with a specialization in “Money, Banking, and Finance” from the UNIVERSITY OF BURGUNDY.
Olivier GIRÉ joined CROSSJECT in 2016 after more than 20 years of experience in the pharmaceutical industry, working with several international specialty laboratories.
Olivier GIRÉ has established and led commercial subsidiaries with over 200 employees and managed international networks comprising more than 50 distributors across nearly 100 countries, including over 12 years with IPSEN, as well as with AMDIPHARM and EXELTIS.
He has extensive expertise in launching innovative medicines and managing pharmaceutical products across a wide range of therapeutic areas, spanning more than ten different specialties.
Olivier GIRÉ is a graduate of EDHEC BUSINESS SCHOOL.
Isabelle LIEBSCHUTZ joined CROSSJECT in 2013, bringing over 17 years of experience in the pharmaceutical industry.
She spent 5 years as part of the “Formulation and Development” team at LABORATOIRES FOURNIER and 7 years as Quality Assurance Manager for the production of transdermal devices, outsourced products, and quality systems on behalf of LABORATOIRES FOURNIER/SOLVAY, covering both European and U.S. markets.
From 2008 to 2013, Isabelle LIEBSCHUTZ held the position of Responsible Pharmacist at a contract manufacturing organization (CMO) specializing in the industrialization and manufacturing of pharmaceutical products and medical devices.
Patrick ALEXANDRE is the Founder and Chairman of the Executive Board of CROSSJECT.
A graduate of SUPÉLEC, he led R&D teams in the steel industry for over 10 years before transitioning to the pharmaceutical industry, where he worked for more than 15 years.
Patrick ALEXANDRE spearheaded the design and development of needle-free injection technology at LABORATOIRES FOURNIER starting in 1997. This activity was transferred to CROSSJECT upon its creation in 2001.
He served as General Manager before being appointed Chairman of the Executive Board in 2012.
Didier MORIN joined CROSSJECT in 2023, bringing extensive experience in industrial operations, production, and R&D. He excels in managing multidisciplinary teams to implement global industrial strategies across various sectors, including medical devices, automotive, and food industries.
Previously, Didier MORIN served for 10 years as Plant Manager and General Manager at IDS and AXESS VISION, two companies specializing in medical devices, where he significantly improved production and operational efficiency.
He holds a Master’s degree in engineering from the Ecole Nationale de Belfort.